Resmed (RSMDF) Accumulated Expenses (2010 - 2026)

Resmed (RSMDF) has reported Accumulated Expenses for 17 consecutive years, with $494.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 23.04% year-over-year to $494.9 million; the trailing twelve-month figure through Jun 2026 stood at $494.9 million (up 23.04% YoY), and the FY2026 full-year result was $494.9 million, up 23.04% from the prior year.
• Accumulated Expenses advanced to $494.9 million in Q2 2026 per RSMDF's latest filing, from $446.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $494.9 million in Q2 2026 and bottomed at $312.2 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $370.5 million across 5 years, with a median of $360.9 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Accumulated Expenses rose 2.51% in 2024, then rose 23.04% in 2026.
• Over 5 years, Accumulated Expenses stood at $312.2 million in 2022, then advanced by 6.4% to $332.1 million in 2023, then increased by 6.14% to $352.5 million in 2024, then advanced by 11.05% to $391.5 million in 2025, then climbed by 26.42% to $494.9 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $494.9 million, $446.1 million, and $391.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.